Tim Harper

With the recent Royal Society survey showing an overwhelming lack of knowledge (and probably accompanying lack of interest) in nanotechnology […]

One of the major problems with drugs is getting them into the body in the first place. With the human

One of the reasons we got into the conference business was our dissatisfaction with the standard scientific conferences. From EuroFE

Hot on the heels of the Elan and Roche deal comes one between Dow Pharma and Bristol-Myers Squibb (which curiously

When it’s a nanoliter – or about this much. Our memories of the confusion between nanofluidics and nanotechnology were jogged

The Finish company Nanos OY visited Stanford Research Institute in Menlo Park, California last week. Markku Rajala – CTO of

Merrill Lynch have made the first set of changes to their index launched appropriately on April 1st. The minor tweaks

Back in the real world, India’s Business Standard reports on the effect that nanotechnology is having on the Indian textile

For reasons that will become obvious in the next few days, we will refrain from commenting on this article in

While some have been lamenting the UKs lack of progress in nanotechnology, industry has been simply getting on with it.